Market Overview:
The global drugs for rheumatoid arthritis market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of rheumatoid arthritis, rising awareness about available treatment options, and growing demand for novel therapies. By type, the prescription drugs segment is expected to account for a larger share of the global drugs for rheumatoid arthritis market in 2018. This segment is also projected to grow at a higher CAGR than the OTC drugs segment during the forecast period. By application, hospitals are expected to account for a larger share of the global drugs for rheumatoid arthritis market in 2018.
Product Definition:
Drugs for rheumatoid arthritis are medications used to treat the symptoms of this condition. These drugs can help to reduce inflammation, pain, and stiffness in the joints. They may also help to slow down the progression of joint damage.
Prescription:
Prescription is a medical procedure given to a patient by a doctor after evaluating the patient’s health condition. In case of arthritis, the doctor may prescribe drugs or recommend surgery or both in combination. The main aim of prescription is to reduce pain and inflammation caused due to arthritis and enable normal functioning of body parts.
OTC:
OTC stands for Over the Counter and it is a category of drugs which can be used by individuals without medical consultation. OTC drugs are usually sold in small quantities, one or two tablets/capsules at a time to consumers who do not have access to healthcare providers. The demand for these medications is increasing rapidly as they are easily available and have no restrictions on their usage like prescription medicines.
Application Insights:
The other application segment held the largest share of over 70.0% in 2017. Other applications include self-medication and online purchasing drugs from foreign countries, which are not approved by the FDA for use in the U.S. The hospital application segment is expected to witness lucrative growth during the forecast period due to rising prevalence of rheumatoid arthritis and increasing awareness about early diagnosis among patients with RA, thus resulting in increased utilization of these drugs at hospitals across various regions including North America, Europe, Asia Pacific and Middle East & Africa.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and high disease prevalence are some of the major factors contributing to its growth. In addition, increasing awareness about early diagnosis is expected to fuel demand for therapeutics in this region. For instance, as per a survey conducted by Arthritis Care & Research Foundation (ACR), in U.S.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising healthcare expenditure by governments and private entities coupled with growing patient awareness levels regarding available treatment options for RA.
Growth Factors:
- Increasing incidence of rheumatoid arthritis
- Growing awareness about the available treatment options for RA
- Rising demand for novel and targeted therapies for RA
- Availability of government funding and insurance coverage for RA drugs
- Technological advancements in the field of rheumatology
Scope Of The Report
Report Attributes
Report Details
Report Title
Drugs for Rheumatoid Arthritis Market Research Report
By Type
Prescription, OTC
By Application
Hospital, Clinics, Other
By Companies
AbbVie Inc, Hoffman-La Roche AG, Amgen Inc, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, UCB Biosciences Inc, Mitsubishi Tanabe Pharma Corp, Biogen Inc, Merck & Co, Market Segment by Product Type, Pharmaceuticals, Biopharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Drugs for Rheumatoid Arthritis Market Report Segments:
The global Drugs for Rheumatoid Arthritis market is segmented on the basis of:
Types
Prescription, OTC
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie Inc
- Hoffman-La Roche AG
- Amgen Inc
- Pfizer Inc
- Bristol-Myers Squibb Co
- Johnson & Johnson
- UCB Biosciences Inc
- Mitsubishi Tanabe Pharma Corp
- Biogen Inc
- Merck & Co
- Market Segment by Product Type
- Pharmaceuticals
- Biopharmaceuticals
Highlights of The Drugs for Rheumatoid Arthritis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prescription
- OTC
- By Application:
- Hospital
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drugs for Rheumatoid Arthritis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one answer to this question as the best drugs for rheumatoid arthritis vary depending on the person's specific symptoms and diagnosis. However, some common medications used to treat rheumatoid arthritis include:nn-TNF inhibitors (such as infliximab or adalimumab)n-COX2 inhibitors (such as celecoxib or rofecoxib)n-DMARDs (disease modifying antirheumatic drugs, such as methotrexate or hydroxychloroquine)
Some of the key players operating in the drugs for rheumatoid arthritis market are AbbVie Inc, Hoffman-La Roche AG, Amgen Inc, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, UCB Biosciences Inc, Mitsubishi Tanabe Pharma Corp, Biogen Inc, Merck & Co, Market Segment by Product Type, Pharmaceuticals, Biopharmaceuticals.
The drugs for rheumatoid arthritis market is expected to grow at a compound annual growth rate of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Drugs for Rheumatoid Arthritis Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Drugs for Rheumatoid Arthritis Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Drugs for Rheumatoid Arthritis Market - Supply Chain
4.5. Global Drugs for Rheumatoid Arthritis Market Forecast
4.5.1. Drugs for Rheumatoid Arthritis Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Drugs for Rheumatoid Arthritis Market Size (000 Units) and Y-o-Y Growth
4.5.3. Drugs for Rheumatoid Arthritis Market Absolute $ Opportunity
5. Global Drugs for Rheumatoid Arthritis Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Type
5.3.1. Prescription
5.3.2. OTC
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Drugs for Rheumatoid Arthritis Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinics
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Drugs for Rheumatoid Arthritis Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Drugs for Rheumatoid Arthritis Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Drugs for Rheumatoid Arthritis Demand Share Forecast, 2019-2026
9. North America Drugs for Rheumatoid Arthritis Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinics
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Type
9.7.1. Prescription
9.7.2. OTC
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Drugs for Rheumatoid Arthritis Demand Share Forecast, 2019-2026
10. Latin America Drugs for Rheumatoid Arthritis Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinics
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Type
10.7.1. Prescription
10.7.2. OTC
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Drugs for Rheumatoid Arthritis Demand Share Forecast, 2019-2026
11. Europe Drugs for Rheumatoid Arthritis Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinics
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Type
11.7.1. Prescription
11.7.2. OTC
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections b Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Drugs for Rheumatoid Arthritis Demand Share, 2019-2026
12. Asia Pacific Drugs for Rheumatoid Arthritis Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinics
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Type
12.7.1. Prescription
12.7.2. OTC
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Drugs for Rheumatoid Arthritis Demand Share, 2019-2026
13. Middle East & Africa Drugs for Rheumatoid Arthritis Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinics
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Drugs for Rheumatoid Arthritis Market Size and Volume Forecast by Type
13.7.1. Prescription
13.7.2. OTC
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Drugs for Rheumatoid Arthritis Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Drugs for Rheumatoid Arthritis Market: Market Share Analysis
14.2. Drugs for Rheumatoid Arthritis Distributors and Customers
14.3. Drugs for Rheumatoid Arthritis Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Hoffman-La Roche AG
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Amgen Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bristol-Myers Squibb Co
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. UCB Biosciences Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mitsubishi Tanabe Pharma Corp
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Biogen Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Merck & Co
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Market Segment by Product Type
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Pharmaceuticals
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Biopharmaceuticals
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook